Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750 · National Cancer Institute (NCI) · PHASE2 · withdrawn · last registry update 2024-05-17 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Other - Protocol moved to Disapproved” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPAT in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-18Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab + Reinduction-2 omission (NCT06882057)
- 2025-03-04Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Venetoclax + Dasatinib (NCT06855810)
- 2024-09-24Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
- 2024-03-12Results posted on the registry: National Cancer Institute (NCI), Clofarabine + Cyclophosphamide (NCT02883049)
- 2024-02-22Also stopped (withdrawn): University of Michigan Rogel Cancer Center, Dasatinib + Ponatinib (NCT04845035)
- 2023-10-13Results posted on the registry: Janssen Research & Development, LLC, Daratumumab + Vincristine (NCT03384654)
- 2023-06-07Results posted on the registry: St. Jude Children's Research Hospital, ITMHA + Dexamethasone (NCT02553460)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision